Ameritas Investment Partners’s NEOPHOTONICS CORP NPTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-4,198
Closed -$66K 3064
2022
Q2
$66K Hold
4,198
﹤0.01% 1813
2022
Q1
$64K Hold
4,198
﹤0.01% 1923
2021
Q4
$65K Hold
4,198
﹤0.01% 1978
2021
Q3
$37K Hold
4,198
﹤0.01% 2356
2021
Q2
$43K Hold
4,198
﹤0.01% 2293
2021
Q1
$50K Buy
4,198
+675
+19% +$7.65K ﹤0.01% 2090
2020
Q4
$32K Hold
3,523
﹤0.01% 2238
2020
Q3
$21K Hold
3,523
﹤0.01% 2365
2020
Q2
$31K Hold
3,523
﹤0.01% 2119
2020
Q1
$26K Buy
3,523
+861
+32% +$6.38K ﹤0.01% 2037
2019
Q4
$23K Hold
2,662
﹤0.01% 2360
2019
Q3
$16K Hold
2,662
﹤0.01% 2525
2019
Q2
$11K Hold
2,662
﹤0.01% 2784
2019
Q1
$17K Hold
2,662
﹤0.01% 2476
2018
Q4
$17K Hold
2,662
﹤0.01% 2447
2018
Q3
$22K Hold
2,662
﹤0.01% 2474
2018
Q2
$17K Hold
2,662
﹤0.01% 2607
2018
Q1
$18K Hold
2,662
﹤0.01% 2491
2017
Q4
$18K Hold
2,662
﹤0.01% 2496
2017
Q3
$15K Hold
2,662
﹤0.01% 2585
2017
Q2
$21K Hold
2,662
﹤0.01% 2431
2017
Q1
$24K Buy
+2,662
New +$27.8K ﹤0.01% 2309

Other funds holding NPTN

Ameritas Investment Partners's NPTN Position: Q3 2022 in Review

Ameritas Investment Partners sold out of NEOPHOTONICS CORP (NPTN) in Q3 2022, closing a stake of 4,198 shares — an estimated $66K sold.

Ameritas Investment Partners first reported a position in NPTN in Q1 2017 and held it in 22 quarters. The position peaked at $66K in Q2 2022. 2 funds tracked by Wall St. Rank hold NPTN as of Q3 2022.

  • Ameritas Investment Partners reported no remaining NEOPHOTONICS CORP position as of Q3 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 4,198 NEOPHOTONICS CORP shares in Q3 2022, an estimated $66K.
  • Ameritas Investment Partners first reported a position in NEOPHOTONICS CORP in Q1 2017 and held it in 22 quarters.
  • Ameritas Investment Partners's NEOPHOTONICS CORP position peaked at $66K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held NEOPHOTONICS CORP as of Q3 2022.

Based on Ameritas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.